TITLE

IP: Time for a Reset?

AUTHOR(S)
Looney, William
PUB. DATE
April 2012
SOURCE
Pharmaceutical Executive;Apr2012, Vol. 32 Issue 4, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on challenges facing pharmaceutical patenters with market uncertainty due to decline in patent filings, conflicting legislation for defining patentability and stalled progress on consensus to extend minimum levels of intellectual property (IP) protection. It reflects that there is an increasing threat from regulator interest in adaptive licensing. It is noted that disruptive innovation also poses an inherent threat to IP.
ACCESSION #
74450290

 

Related Articles

  • The Shifting Landscape of Patent Licensing. Carter, Jennifer // BioPharm International;Sep2007, Vol. 20 Issue 9, p32 

    The article focuses on the issue concerning the Supreme Court ruling in the Midlmmune v. Genentech case shifted the landscape of patent licensing in an essential process. As its result, a patent licensee now can challenge the validity of a patent without having to breach the license first. It...

  • Destination: INDIA. Das, Rahul; Sharma, Anand K. // Drug Discovery & Development;Aug2007, Vol. 10 Issue 8, p35 

    The article focuses on India as an ideal venue for doing business related to drug discovery and development due to its patent considerations. It offered patent protection for pharmaceutical products and services including outsourcing and collaborations. Its outsourcing model entailed an alliance...

  • RECONSIDER[NG IN RE TECHNOLOGY LICENSING CORPORATION AND THE RIGHT TO JURY TRIAL IN PATENT INVALIDITY SUITS. Bateman, Andrew W. // Chicago-Kent Law Review;2007, Vol. 82 Issue 2, p933 

    The article discusses the Federal Circuit court ruling on the "In re Technology Licensing Corporation" case in the U.S. The court held that there is no right to a jury trial in a declaratory judgment action that seeks a declaration of patent invalidity, where the defendant counterclaims with...

  • The time for pharmaceutical compulsory licensing has expired. Kuhn, Randall; Beall, Reed F // Nature Medicine;Aug2012, Vol. 18 Issue 8, p1168 

    The authors discuss an announcement by the State Intellectual Property Office of China, in which revision to country's patent law is made that will make the compulsory license mechanism easier to pharmaceutical companies. They state that the threat of compulsory licenses did play a part in...

  • Compulsory Licenses Under Trips and Its Obligations for Member Countries. Jain, Tarunz // ICFAI Journal of Intellectual Property Rights;Feb2009, Vol. 8 Issue 1, p27 

    The present status of the compulsory license is reached after evolving through a longer period and referred in various conventions relating to intellectual property rights such as the Rome Convention, Paris Convention and Berne Convention etc., though the concept existed even before. Article 31...

  • The Role of Compulsory Licensing in Unilateral Refusals to Deal: Have the United States and European Approaches Grown Further Apart After IMS? Reichenberger, Melanie J. // Journal of Corporation Law;Winter2006, Vol. 31 Issue 2, p549 

    The article analyzes the role of compulsory licensing in contracts between businesses. One debate between the European Union and the U.S. is to find a balance between the inherent tension between intellectual property laws and antitrust laws. Several recommendations include the use of compulsory...

  • SOVIET PATENT POLICY: NEW INCENTIVES FOR THE INVENTOR. Kiron, Allan // Bulletin of the Atomic Scientists;Dec1963, Vol. 19 Issue 10, p12 

    The article reports on issues and topics related to the policies governing patents and intellectual rights in the Soviet Union. In 1960 alone, the sale of patent licenses among companies in the West amounted to almost one billion dollars. However, Russian patents enjoy no such return, in part...

  • Intellectual Property Laws. Stuart, Michael // Pharmaceutical Technology;Jul2006, Vol. 30 Issue 7, p94 

    The article discusses the author's insights which pertain to intellectual property laws to be applied for the protection of pharmaceutical companies from competitive challenges. Pharmaceutical companies understand the benefits and boundaries of intellectual property as their valuable group of...

  • Patent Strategies in the European Union for the Pharmaceutical Industry. Cohen, Larry; Uphoff, Boris // Venulex Legal Summaries;2003 Q1, p1 

    The article discusses the need for a community patent in the pharmaceutical industry in the European Union. The advantages of a community patent are cited. The cost of obtaining the patent is reported. The reason behind a strong political pressure for the implementation of a community patent is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics